Home > Boards > US OTC > Miscellaneous > Therapeutic Solutions International, Inc. (TSOI)

Re: Nano PSA

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
centsability4me Member Profile
Member Level 
Followed By 33
Posts 3,251
Boards Moderated 3
Alias Born 06/17/13
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 11/12/2019 4:05:22 PM
Therapeutics Solutions International Signs Agreement with Beijing Regenesis Biotechnology InvestorsHub NewsWire - 11/11/2019 9:00:00 AM
Therapeutics Solutions International Reports Augmentation of Rejuvenating Activity of Cord Blood Plasma by Pterostilbene InvestorsHub NewsWire - 11/4/2019 9:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/9/2019 12:59:28 PM
Therapeutic Solutions International Reports NanoStilbene™ Protects the Immune System from Cancer Chemotherapy InvestorsHub NewsWire - 9/9/2019 9:00:00 AM
Feng Lin, MD, Ph.D., Joins Therapeutic Solutions International as Chief Scientific Officer InvestorsHub NewsWire - 9/3/2019 9:00:00 AM
Therapeutic Solutions International, Inc. Reports Revenues Up 850% for Q2 and 850% for 1st 6 months InvestorsHub NewsWire - 8/29/2019 9:00:00 AM
Therapeutic Solutions International Announces Positive Clinical Data Using NanoStilbene™ to Stimulate Immune System InvestorsHub NewsWire - 8/26/2019 9:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/16/2019 4:28:47 PM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 8/13/2019 1:46:36 PM
Therapeutic Solutions International Collaborates with Right to Try Foundation on Novel Means of Protecting Patients InvestorsHub NewsWire - 8/5/2019 9:00:00 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 7/30/2019 4:44:49 PM
NanoStilbene™ Nutraceutical Shown to Increase Ability of Cyclophosphamide Chemotherapy to Suppress Cancer InvestorsHub NewsWire - 7/29/2019 9:00:00 AM
Therapeutic Solutions International Reports its NanoStilbene™ Nutraceutical Product Enhances Efficacy of FDA Cleared Ca... InvestorsHub NewsWire - 7/22/2019 9:00:00 AM
Therapeutic Solutions International adds Nano Cannabidiol to NanoMyros for Inhibition of Microvesicle and Exosome Release InvestorsHub NewsWire - 7/15/2019 9:00:00 AM
Therapeutic Solutions International Develops Adjuvant Technology to Enhance Prostate Cancer Suppressing Properties of InvestorsHub NewsWire - 7/11/2019 9:00:00 AM
Therapeutic Solutions International Develops Glucoraphanin + NanoStilbene Encapsulated product InvestorsHub NewsWire - 7/8/2019 9:00:00 AM
Therapeutic Solutions International Obtains Exclusive License for Patented Clinical Stage Adult Stem Cell for Treatment of InvestorsHub NewsWire - 7/1/2019 9:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/19/2019 11:12:46 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/20/2019 11:18:31 AM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 5/14/2019 11:22:33 AM
Therapeutic Solutions International Awards Distribution of NanoStilbene and Nano Cannabidiol in Mexico to Immun ET Laboratori... InvestorsHub NewsWire - 5/6/2019 9:00:00 AM
Annual Report (10-k) Edgar (US Regulatory) - 4/15/2019 1:36:47 PM
Notification That Annual Report Will Be Submitted Late (nt 10-k) Edgar (US Regulatory) - 3/29/2019 11:33:18 AM
Therapeutic Solutions International Continues to Refine NanoStilbene™ Formulation InvestorsHub NewsWire - 2/19/2019 9:00:00 AM
centsability4me Member Level  Thursday, 10/17/19 12:58:30 PM
Re: centsability4me post# 12514
Post # of 12724 
Re: Nano PSA
TSOI follow through counts for somethin in my book .
Nano PSA is on the shelf now , and was announced on July 8th this year .
https://markets.businessinsider.com/news/stocks/therapeutic-solutions-international-develops-glucoraphanin-nanostilbene-encapsulated-product-for-reduction-of-prostate-specific-antigen-psa-1028335148


Therapeutic Solutions International Develops Glucoraphanin + NanoStilbene Encapsulated product for reduction of Prostate Specific Antigen (PSA)
PRESS RELEASE GlobeNewswire
Jul. 8, 2019, 09:00 AM

OCEANSIDE, Calif., July 08, 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI) announced today the development of a broccoli sprout extract containing the precursor glucoraphanin in a combined 200mg dose of NanoStilbene.

As previously announced, the same NanoStilbene that was administered to 12 patients with advanced solid cancers for three weeks is the base for this new product we are calling "NanoPSA." Daily treatment with 300mg of NanoStilbene caused reduction in serum levels of inflammatory markers TNF-alpha, IL-6, and CRP [1]. Additionally, NK cytotoxicity was augmented, suggesting that NanoStilbene may be a useful adjuvant to immunotherapy of cancer rescuing T-cell and NK cell activities. These same inflammatory molecules are involved in elevated levels of PSA.

Glucoraphanin, found primarily in broccoli, is another potent antioxidant like pterostilbene. The main purpose of antioxidants is to protect the cells in our body from damage caused by oxidative stress, namely free radicals, which are unstable compounds missing an electron. This free radical damage is also closely linked with inflammation because the body recognizes oxidative damage as a threat.

We know what the result is, a damaging cycle of oxidation: damage – immune cells – more damage. Increasing antioxidant potential in the body provides a solution by helping to prevent a lot of the oxidative damage in the first place.

Glucoraphanin, as we have produced it, is a precursor to our end product, which is another compound called sulforaphane. Glucoraphanin belongs to a category of compounds called glucosinolates which are naturally found in cruciferous vegetables. Glucosinolates are enzymatically converted into isothiocyanates, which are active in the body. This enzymatic conversion is performed by myrosinase, which is also found naturally in cruciferous vegetables. Myrosinase-like activity also occurs in our intestinal microflora, so if glucoraphanin is consumed by itself, our gut microflora will convert a portion of it to sulforaphane, a compound within the isothiocyanate group of organosulfur compounds.

"This is an extremely exciting development in our research with our end target compound being sulforaphane. Sulforaphane has been shown to significantly reduce PSA after 20 weeks of consuming broccoli sprout extract (BSE). There is little misunderstanding that inflammation causes gut dysbiosis, and since we are depending upon the microflora to hydrolyze the glucoraphanin into sulforaphane, it seems perfectly reasonable to want the gut in the best shape it can be in. We already know pterostilbene supplementation causes beneficial changes in microbiota composition, improved metabolic function, strengthened insulin sensitivity and induced anti-obesity effects and so we have blended the two into a single formulation, providing a clinically relevant amount of both actives. Our mission is to either up-regulate or down-regulate the immune system, and NanoPSA is another tool in the box to achieve our mission," said Timothy Dixon, president and CEO of Therapeutic Solutions International. "We hope to have this product available, which will come in capsule form, on the shelf very quickly."

[1] https://mynanostilbene.com/?page_id=137

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist